The latest breakthrough in biotechnology has just been unveiled by GenScript Biotech, a global leader in the field. The Life Sciences subsidiary, GenScript, has introduced the AmMag™ Quatro Mini-1100, a cutting-edge DNA purification platform that promises high yields and low endotoxin levels. This innovative instrument complements the existing AmMag Quatro Maxi-1400, expanding the company’s range of solutions for plasmid purification.
Advanced Technology for Optimal Results
The AmMag Quatro Mini-1100 is a fully automated system designed for mini-scale plasmid purification. With the ability to process up to 192 samples per run and handle volumes from 1 to 10 mL, this high-throughput platform guarantees consistent, top-quality outcomes with minimal endotoxin contamination. Its versatility makes it suitable for various applications, such as gene therapy research, vaccine development, CRISPR and gene editing, cell line development, and synthetic biology.
Expert Endorsement
Paul Wu, the Vice President of R&D for GenScript’s Catalog Products Division, expressed the company’s commitment to providing researchers with flexible and scalable options tailored to their specific requirements. The success of the AmMag product line, including the Maxi-1400 scale system, has already established new benchmarks in plasmid purification. Researchers from leading biotechnology firms like TScan Therapeutics, Valent BioSciences, and Incyte have lauded the efficiency and reliability of the AmMag performance in cancer research, biopharmaceuticals, and sustainable agriculture.
Enhanced Research Support
With the launch of the AmMag Quatro Mini-1100, GenScript has further bolstered its portfolio to meet the evolving needs of modern laboratories. By offering specialized systems for both mini- and maxi-preparations, labs can now access high-quality plasmid DNA ready for transfection. The AmMag Quatro Mini-1100 is currently available for purchase, and interested parties can visit GenScript’s website for additional details.
In conclusion, GenScript continues to lead the way in advancing scientific discovery and therapeutic breakthroughs through its innovative technologies and services. With a global presence and a dedicated team of over 5400 employees, GenScript remains committed to making a positive impact on people and nature through biotechnology. For media inquiries, please contact Michelle Simayi at [email protected] Let’s embrace this cutting-edge technology together and unlock new possibilities in the world of biotechnology!
